Bode U - Search Results

1

Liposomal amphotericin B can safely be administered in paediatric outpatients with cancer for the primary or secondary prevention of invasive aspergillosis.

Simon A, Bode U, Maul M, Fleischhack G. Simon A, et al. Among authors: bode u. Acta Haematol. 2007;118(2):68-9. doi: 10.1159/000102605. Epub 2007 May 29. Acta Haematol. 2007. PMID: 17538246 No abstract available.

2

Pancreatic toxicity after liposomal amphotericin B.

Stuecklin-Utsch A, Hasan C, Bode U, Fleischhack G. Stuecklin-Utsch A, et al. Among authors: bode u. Mycoses. 2002 Jun;45(5-6):170-3. doi: 10.1046/j.1439-0507.2002.00744.x. Mycoses. 2002. PMID: 12100534

3

Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports.

Zernikow B, Fleischhack G, Hasan C, Bode U. Zernikow B, et al. Among authors: bode u. Mycoses. 1997 Dec;40(9-10):359-61. doi: 10.1111/j.1439-0507.1997.tb00250.x. Mycoses. 1997. PMID: 9470422

4

Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.

Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U, Fleischhack G. Simon A, et al. Among authors: bode u. Support Care Cancer. 2007 Feb;15(2):213-20. doi: 10.1007/s00520-006-0125-7. Epub 2006 Aug 30. Support Care Cancer. 2007. PMID: 16944217

5

Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.

Simon A, Gröger N, Wilkesmann A, Hasan C, Wiszniewsky G, Engelhart S, Kramer MH, Bode U, Ammann RA, Fleischhack G. Simon A, et al. Among authors: bode u. Int J Antimicrob Agents. 2006 Nov;28(5):417-22. doi: 10.1016/j.ijantimicag.2006.08.007. Epub 2006 Oct 12. Int J Antimicrob Agents. 2006. PMID: 17046210

6

Influence of prolonged use of intravenous administration sets in paediatric cancer patients on CVAD-related bloodstream infection rates and hospital resources.

Simon A, Fleischhack G, Wiszniewsky G, Hasan C, Bode U, Kramer MH. Simon A, et al. Among authors: bode u. Infection. 2006 Oct;34(5):258-63. doi: 10.1007/s15010-006-5646-y. Infection. 2006. PMID: 17033749

7

Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.

Simon A, Bode U, Lieber K, Beutel K, Fleischhack G. Simon A, et al. Among authors: bode u. Am J Infect Control. 2008 Feb;36(1):54-8. doi: 10.1016/j.ajic.2007.02.007. Am J Infect Control. 2008. PMID: 18241737 Review.

8

Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.

Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Simon A, et al. Among authors: bode u. BMC Infect Dis. 2008 Jul 29;8:102. doi: 10.1186/1471-2334-8-102. BMC Infect Dis. 2008. PMID: 18664278 Free PMC article.

9

Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients.

Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Simon A, et al. Among authors: bode u. Infect Control Hosp Epidemiol. 2000 Sep;21(9):592-6. doi: 10.1086/501809. Infect Control Hosp Epidemiol. 2000. PMID: 11001263

10

Surveillance of nosocomial infections in pediatric cancer patients.

Simon A, Bode U, Fleischhack G, Kramer M. Simon A, et al. Among authors: bode u. Am J Infect Control. 2005 Dec;33(10):611. doi: 10.1016/j.ajic.2005.09.005. Am J Infect Control. 2005. PMID: 16330311 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters